Aspen Pharmacare in South Africa, which is Africa’s first COVID vaccine plant, will shut down due to a drop in demand for the vaccine.
The first facility in Africa to create COVID-19 "vaccines" is about to close. Despite assurances from COVAX and others that there would be sufficient demand for Africa's only COVID vaccine, the continent's largest pharmaceutical company has received no orders.
Late last year, Aspen Pharmacare in South Africa inked a licensing arrangement to bottle and distribute Johnson & Johnson's COVID-19 "vaccine," but six months later, demand for the shot has dropped significantly, putting the plans in jeopardy.
Early in the pandemic, Africa was left out of the rush for vaccines, and the license agreement was regarded as a lifeline for the continent by many, including the World Health Organization (WHO).
The refusal to acquire the "vaccine," according to the Financial Times, demonstrates waning demand in South Africa and is part of a broader t...